Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma

• US 20050287541A1
• Filed: 09/23/2004
• Published: 12/29/2005
• Est. Priority Date: 09/25/2003
• Status: Active Grant

• Current Assignee: Chiba-Prefecture, Hisamitsu Pharmaceutical Company Incorporated
• Original Assignee: Chiba-Prefecture, Hisamitsu Pharmaceutical Company Incorporated, NGK Insulators Limited
• Inventors: Yoshida, Yasuko, Ishii, Shin, Ohira, Miki, Yamada, Saichi, Goto, Takeshi, Nakagawara, Akira, Kubo, Hiroyuki, Hirata, Takahiro
• Granted Patent: US 7,601,532 B2
• Time in Patent Office: Days
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development

Abstract

A microarray for predicting the prognosis of neuroblastoma, wherein the microarray has 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 1 to 96 or their partial continuous sequences or their complementary strands, and 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 97 to 200 or their partial continuous sequences or their complementary strands.

Claims

1. A microarray having 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 1 to 96 or their partial continuous sequencesor their complementary strands, and 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 97 to 200 or their partial continuous sequences or their complementary strands.

2. A method for predicting prognosis of neuroblastoma using the microarray of claim 1, which comprises:

(a) a step of labeling a gene transcript obtained from a tumor cell of a patient diagnosed as having neuroblastoma;

(b) a step of bringing the labeled gene transcript into contact with said microarray;

(c) a step of measuring the labeling signal of each of the gene transcripts hybridized to 25 to 45 probes related to good prognosis and 25 to 45 probes related to poor prognosis on the microarray, respectively, and

determines that the prognosis of the patient is good if significant labeling signals for 25 or more of the probes related to good prognosis were obtained, and that the prognosis of the patient is poor if significant labeling signals for 25 or more of the probes related to poor prognosis were obtained.